Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

The deal, disclosed on Wednesday 5 March, will see Jazz pay $8.55 per share, representing a 72.4% premium to Chimerix’s 4 ...

Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.

Dordaviprone is designed to activate stress responses in cancer cells, pushing them into apoptosis by acting on the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). According to ...

Jazz Pharma to buy biopharmaceutical company, Chimerix for approximately $935 million: Dublin Friday, March 7, 2025, 14:00 Hrs [IST] Jazz Pharmaceuticals plc, a global biopharmace ...

Experiments in rats suggest that reduced dopamine receptor availability in the ... Rats selected in this way also had reduced levels of available DRD2 in ventral striata, as detected by ...

Dordaviprone (ONC201) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). Dordaviprone's unique mechanism of ...